PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy (Q38861792)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

based on heuristic

inferred from title

author name string

Georg Nuebling

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Mira Hensler

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sabine Paul

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Andreas Zwergal

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Alexander Crispin

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Stefan Lorenzl

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

publication date

26 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

263

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1565-1574

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

New insights into progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Progressive supranuclear palsy: clinical features, pathophysiology and management

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

A clinical rating scale for progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

FAB-D: German version of the Frontal Assessment Battery

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Postural imbalance with head extension: improvement by training as a model for ataxia therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Rate of decline in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Depression rating scales in Parkinson's disease: critique and recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Postural imbalance and falls in PSP correlate with functional pathology of the thalamus

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Functional disturbance of the locomotor network in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

21 January 2018

Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27230855

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective study of drug response in 87 patients with progressive supranuclear palsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27230855

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-016-8169-1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38861792&oldid=2202194470"